Akebia Therapeutics, Inc.
AKBA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $59 | $62 | $57 | $46 |
| % Growth | -5.9% | 9% | 23.3% | – |
| Cost of Goods Sold | $10 | $10 | $8 | $20 |
| Gross Profit | $49 | $53 | $50 | $26 |
| % Margin | 83.5% | 84.1% | 86.7% | 56.2% |
| R&D Expenses | $15 | $11 | $10 | $12 |
| G&A Expenses | $0 | $0 | $0 | $23 |
| SG&A Expenses | $30 | $27 | $26 | $28 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $5 |
| Other Operating Expenses | $0 | $1 | $1 | $1 |
| Operating Expenses | $45 | $38 | $36 | $40 |
| Operating Income | $4 | $14 | $14 | -$14 |
| % Margin | 7.6% | 22.6% | 23.6% | -30.8% |
| Other Income/Exp. Net | -$3 | -$14 | -$7 | -$8 |
| Pre-Tax Income | $1 | $0 | $6 | -$23 |
| Tax Expense | $1 | $0 | $0 | $0 |
| Net Income | $1 | $0 | $6 | -$23 |
| % Margin | 0.9% | 0.4% | 10.7% | -49% |
| EPS | 0.002 | 0.001 | 0.026 | -0.1 |
| % Growth | 122.2% | -96.5% | 126% | – |
| EPS Diluted | 0.002 | 0.001 | 0.025 | -0.1 |
| Weighted Avg Shares Out | 265 | 263 | 235 | 219 |
| Weighted Avg Shares Out Dil | 274 | 271 | 242 | 219 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $5 | $7 | $8 | $7 |
| Depreciation & Amortization | $0 | $0 | $0 | $9 |
| EBITDA | $6 | $7 | $14 | -$7 |
| % Margin | 10.6% | 11.8% | 24.8% | -14.2% |